Optimal drug administration of mixed cytotoxic and immunostimulating agents for cancer treatment via multi-objective optimization
DOI:
https://doi.org/10.5902/2179460X87129Keywords:
Cancer Treatment, Chemotherapy, Immunotherapy, Optimal Control, Multi-objective OptimizationAbstract
Cancer represents a significant concern in terms of global public health, standing out as one of the main causes of death and a barrier to the advancement of life expectancy. The costs associated with cancer treatment have grown above the rate of inflation, driven by the increase in the number of new patients diagnosed, costs of materials and drugs involved, and inefficiency of care, which is becoming increasingly complex and uncoordinated. The mixed administration of immunotherapy and chemotherapy drugs plays a key role in cancer treatment. However, such treatments combination can present challenges arising from the complex interactions between these two therapeutic modalities. This work aims to identify the optimal combination of treatments that allows for minimizing both the tumor volume and the adverse effects resulting from the joint administration of drugs through a multi-objective optimization approach, establishing guidelines for optimal drug administration in the context of combined immunotherapy and chemotherapy.
Downloads
References
Borcoman, E., Kanjanapan, Y., Champiat, S., Kato, S., Servois, V., Kurzrock, R., Goel, S., Bedard, P., Le Tourneau, C. (2019).
Novel patterns of response under immunotherapy. Annals of Oncology, 30(3), 385–396.
Chaplain, M., Matzavinos, A. (2006). Mathematical modelling of spatio-temporal phenomana in tumour immunology. Lecture
Notes in Mathematics, 1872.
Deb, K. (2001). Multi-objective optimization using evolutionary algorithms, vol 1. John Wiley & Sons, Inc, England.
Deb, K., Pratap, A., Agarwal, S., Meyarivan, T. (2002). A fast and elitist multiobjective genetic algorithm: NSGA-II. IEEE
Transactions on Evolutionary Computation, 6.
D’Onofrio, A., Ledzewicz, U., Schättler, H. (2012). On the Dynamics of Tumor-Immune System Interactions and Combined
Chemo- and Immunotherapy. Em: d’Onofrio, A., Cerrai, P., Gandolfi, A. (Eds) SEMA SIMAI Springer Series, Springer Milan,
Milano, pp. 249–266.
Kuznetsov, V. A., Makalkin, I. A., Taylor, M. A., Perelson, A. S. (1994). Nonlinear dynamics of immunogenic tumors: Parameter
estimation and global bifurcation analysis. Bulletin of Mathematical Biology, 56.
Lake, R. A., Robinson, B. W. (2005). Immunotherapy and chemotherapy - a practical partnership. Nature Reviews Cancer, 5.
Laleh, N. G., Loeffler, C. M. L., Grajek, J., Staˇnková, K., Pearson, A. T., Muti, H. S., Trautwein, C., Enderling, H., Poleszczuk, J.,
Kather, J. N. (2022). Classical mathematical models for prediction of response to chemotherapy and immunotherapy. PLoS
Computational Biology, 18.
Ledzewicz, U., Schättler (2020). On the role of the objective in the optimization of compartmental models for biomedical therapies.
Journal of Optimization Theory and Applications, 187.
Ledzewicz, U., Naghnaeian, M., Schättler, H. (2011a). Dynamics of tumor-immune interaction under treatment as an optimal
control problem. Discrete and Continuous Dynamical Systems- Series A.
Ledzewicz, U., Naghnaeian, M., Schättler, H. (2011b). An optimal control approach to cancer treatment under immunological
activity. Applicationes Mathematicae, 38.
Ledzewicz, U., Naghnaeian, M., Schättler, H. (2012). Optimal response to chemotherapy for a mathematical model of tumor-
immune dynamics. Journal of Mathematical Biology, 64.
Norton, L. (1988). A gompertzian model of human breast cancer growth. Cancer Research, 48.
Norton, L., Simon, R. (1977). Growth curve of an experimental solid tumor following radiotherapy. Journal of the National
Cancer Institute, 58.
Pillis, L. G. D., Fister, K. R., Gu, W., Head, T., Maples, K., Neal, T., Murugan, A., Kozai, K. (2008). Optimal control of mixed
immunotherapy and chemotherapy of tumors. Journal of Biological Systems, 16.
Stepanova, N. V. (1979). Course of the immune reaction during the development of a malignant tumour. Biophysics, 24.
Tan, S., Li, D., Zhu, X. (2020). Cancer immunotherapy: Pros, cons and beyond. Biomedicine and Pharmacotherapy, 124.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ciência e Natura
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
To access the DECLARATION AND TRANSFER OF COPYRIGHT AUTHOR’S DECLARATION AND COPYRIGHT LICENSE click here.
Ethical Guidelines for Journal Publication
The Ciência e Natura journal is committed to ensuring ethics in publication and quality of articles.
Conformance to standards of ethical behavior is therefore expected of all parties involved: Authors, Editors, Reviewers, and the Publisher.
In particular,
Authors: Authors should present an objective discussion of the significance of research work as well as sufficient detail and references to permit others to replicate the experiments. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable. Review Articles should also be objective, comprehensive, and accurate accounts of the state of the art. The Authors should ensure that their work is entirely original works, and if the work and/or words of others have been used, this has been appropriately acknowledged. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable. Authors should not submit articles describing essentially the same research to more than one journal. The corresponding Author should ensure that there is a full consensus of all Co-authors in approving the final version of the paper and its submission for publication.
Editors: Editors should evaluate manuscripts exclusively on the basis of their academic merit. An Editor must not use unpublished information in the editor's own research without the express written consent of the Author. Editors should take reasonable responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper.
Reviewers: Any manuscripts received for review must be treated as confidential documents. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should be conducted objectively, and observations should be formulated clearly with supporting arguments, so that Authors can use them for improving the paper. Any selected Reviewer who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the Editor and excuse himself from the review process. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.